Skip to content
Home - Media - Press releases - 2002    
22 October 2002
ASTRAZENECA LOSES UK APPEAL ON OMEPRAZOLE FORMULATION PATENTS

AstraZeneca today announced that the Court of Appeal in London has denied its request for a re-trial following an earlier decision of the United Kingdom’s Patents Court in a dispute with the generic pharmaceutical companies, Arrow Generics Limited (acting through Cairnstores Limited) and Generics UK Limited, about formulation patents for omeprazole – the active substance used in Losec, a treatment for acid-related disorders, such as peptic ulcers.

The Court of Appeal refused to allow a re-trial due to the bias shown by the Patents Court judge in the original hearing, and the decision in March (2002) of the Patents Court of the High Court Chancery Division, which declared the formulation patents (EP 247 983 and EP 496 437) invalid due to obviousness, was affirmed.

The UK represented 4.3 percent of Losec’s worldwide sales in 2001.

October 22, 2002

Further enquires to:

Media Enquiries

Steve Brown
+44 (0)20 7304 5033

Emily Denney
+44 (0)20 7304 5034


Investor Relations

Jonathan Hunt
+44 (0)20 7304 5087

Mina Blair-Robinson
+44 (0)20 7304 5084

AstraZeneca websites
Search